Update on Invasive Fungal Disease: Expert Perspectives on Treatment Paradigms

This interactive video module reviews the epidemiology and outcomes trends for IFI in high-risk patients, guideline recommendations for primary antifungal therapy, and the advantages and disadvantages of current treatment options.

Thomas F. Patterson, MD, FACP, FIDSA
Program Director James Lewis, PharmD, FIDSA George R. Thompson III, MD, FIDSA Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 24, 2019 Expired: No longer available for credit

This interactive video module examines risk stratification, nonpharmacologic strategies to reduce fungal exposure, guideline recommendations for prophylactic therapy, and management of breakthrough infections.

Thomas F. Patterson, MD, FACP, FIDSA
Program Director James Lewis, PharmD, FIDSA George R. Thompson III, MD, FIDSA Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 24, 2019 Expired: No longer available for credit

This interactive video module highlights areas of unmet medical need in the prevention and treatment of IFIs as well as ongoing efforts to address these barriers including new uses for established agents and the development of novel agents with unique mechanisms of action.

Thomas F. Patterson, MD, FACP, FIDSA
Program Director James Lewis, PharmD, FIDSA George R. Thompson III, MD, FIDSA Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 24, 2019 Expired: No longer available for credit

Review guideline recommendations for primary antifungal therapy in high-risk patients as well as the benefits and risks of specific agents.

Thomas F. Patterson, MD, FACP, FIDSA
Program Director James Lewis, PharmD, FIDSA Released: April 24, 2019

Learn to risk stratify patients, select optimal prophylactic therapy, and manage breakthrough fungal infections with this downloadable slideset.

Thomas F. Patterson, MD, FACP, FIDSA
Program Director George R. Thompson III, MD, FIDSA Released: April 24, 2019

Gain insight on strategies under investigation to address barriers to effective prevention and treatment of invasive fungal infections. Learn about new uses for existing agents, new agents in currently used classes, and new compounds with unique mechanisms of action.

Thomas F. Patterson, MD, FACP, FIDSA
Program Director Released: April 24, 2019